USFDA concludes inspection at Cipla’s Goa manufacturing facility
On conclusion of the inspection, the Company received two inspectional observations in Form 483
United States Food and Drug Administration (USFDA) has completed an inspection at Cipla’s manufacturing facility in Verna, Goa, India. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI). USFDA had conducted the inspection at said facility from April 06 to April 17, 2025.
On conclusion of the inspection, the Company received two inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
